Akebia Announces Positive Top-Line Results from INNO2VATE – Global Phase 3 Program for Vadadustat

Akebia’s Response to COVID-19

As a member of the renal community, the health of our patients and employees is our first priority.

For patients in the U.S. taking a prescribed Akebia product, please visit or call 855-686-8601 for assistance.


Making a difference by
challenging the status quo


We are better together


A trusted leader in the renal community delivering new therapeutic options to people with kidney disease.

We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development. Vadadustat and HIF-PHI are based on Nobel Prize-winning science.

Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.

Be part of a passionate team working to protect the kidneys and to innovate for better lives

Nearly 37 million Americans

are currently affected by chronic kidney disease.

Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: Accessed: September 3, 2019.

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us